ACTA1 and Hepatic fibrosis: Administration of miR-122-enriched AD-MSC EVs in CCl4-treated mice resulted in attenuation of hepatic fibrosis, suppression of hepatic TGF-β1 and αSMA expression, and inhibition of serum ALT, hyaluronan, type III procollagen, aspartate transaminase and liver hydroxyproline [275] while mir-150-5p-enriched AD-MSC EVs were anti-fibrotic due to targeting of CXCL1 [276].